UNIONDALE, N.Y.--(BUSINESS WIRE)--ImaCor announces that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the ClariTEE™ probe and the ZuraTM imaging system. The ClariTEE probe is a miniaturized transesophageal echocardiography probe which facilitates episodic monitoring of cardiac function. The ClariTEE is a single use device that can remain indwelling for up to 72 hours, allowing intensivists and anesthesiologists to periodically assess cardiac preload and left ventricular systolic function over a prolonged period of time.
“ImaCor believes that the ClariTEE probe will be a major contribution to the care of the critically ill, especially in ICU and perioperative situations,” said Scott L. Roth, MD, Chief Executive Officer and a founder of ImaCor. “Current methods of monitoring hemodynamics in this patient population are either invasive, inconclusive, or both. The ClariTEE probe is minimally invasive and allows physicians to directly visualize cardiac size and function, and to assess changes as pharmacologic interventions are made,” adds Roth.
“This is a technology that intensive care physicians have been waiting for,” says Dr. Alexander Levitov, Critical Care section chief at Carilion Roanoke Memorial Hospital in Virginia. Levitov adds, “The ClariTEE probe has the potential to become the standard of care in managing hemodynamically unstable patients in the ICU.”
About Imacor
ImaCor, LLC is a privately held company headquartered in Uniondale, NY. The company designs, manufactures, and distributes advanced solutions for monitoring cardiac function in the critical care environment, for the purpose of improving patient outcomes. ZuraTM and ClariTEETM are trademarks of ImaCor, LLC. For more information, please visit our website at www.imacormonitoring.com.
Contacts
ImaCor, LLC
Dipak Rajhansa, 516-393-0970
drajhansa@imacormonitoring.com
